All antibodies were used accordingly to the manufacturer’s instructions. After 20 min of incubation, erythrocytes were lysed with 1 mL of VersaLyse

(BC, A09777). Before acquisition, 100 μl Flow-Count Alectinib manufacturer Fluorospheres (BC, 7547053) were added to the test tube. Post-acquisition, the data were analyzed with the Kaluza software (BC). Briefly, the DNA marker Syto 40 was used to exclude cellular debris (i.e. negative) and 7-amino-actinomycin D (7-AAD) was used for dead and live cell discrimination and therefore for assessing the cellular viability [10] and [18]. ASCs were identified in the CD45 and CD146 negative and CD34 positive fraction [6] and [21]. Finally,

Flow-Count Fluorospheres were used to directly determinate the absolute number of ASCs by applying the formula: Absolute Count (cells/μl) = (Total Number of Cells Counted/Total Number of Fluorospheres Counted) × Flow-Count Fluorospheres Assayed Concentration. The CFU-F assay was performed as already described elsewhere and used to evaluate the frequency of mesenchymal progenitors in the SVF fraction. Therefore, freshly extracted nucleated cells were plated at two cell concentrations (5000 and 10,000 cells) in standard 100 × 20 mm tissue culture www.selleckchem.com/products/z-vad-fmk.html dishes (growth area 58.95 cm2, BD Falcon, Basel, Switzerland) and cultured in MEM/5% converted human serum/1% antibiotics for 14 days. The plates were then washed with DPBS, fixed in 2% formaldehyde (Sigma–Aldrich, Buchs, Switzerland)/0.2% Glutaraldehyde (AppliChem, Darmstadt, Germany) for 5 min and stained with crystal violet solution (Sigma–Aldrich, Buchs, Switzerland) for 10 min. After washing the plates with water, the number of colonies were (-)-p-Bromotetramisole Oxalate counted. A colony consisting of more than 50 cells was defined as a CFU-F. Fresh SVF cells were centrifuged 5 min at 400g, re-suspended in 25 ml ice-cold solution of injectable 5% human albumin solution with 5% ME2SO (Dimethylsulfoxide, WAK-Chemie Medical GmbH, Steinbach, Germany) and transferred into

a freezing 25 ml cryobag (Pall Europe Ltd., Portsmouth, England). Cells were frozen by means of a programmable freezer (Consartic GmbH, Schoellkrippen, Germany) under the following “controlled-rate” conditions: from 4 °C to 0 °C in 6 min, then hold for 15 min at 0 °C. From 0 °C to −2 °C in 9 min and then hold for 2 min at −2 °C. From −2 °C to −35 °C in 25.5 min and finally from −35 °C to −100 °C in 13 min. For what regards thawing, the cryobag was immersed in a 37 °C water bath for 2–3 min. Immediately after being thawed, the cells were carefully aspirated, mixed with an equal volume of injectable 5% human albumin solution in a 50 ml TPP conical tube and centrifuged at 400g for 5 min.